XML 316 R288.htm IDEA: XBRL DOCUMENT v3.25.1
Business - Additional Information (Detail)
$ in Thousands
1 Months Ended 12 Months Ended
Apr. 15, 2025
Apr. 01, 2025
Dec. 19, 2024
shares
Jun. 14, 2024
Jan. 31, 2024
Dec. 31, 2024
USD ($)
Offering
shares
Mar. 31, 2025
USD ($)
Mar. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Nature Of Business [Line Items]                      
Stockholders' equity           $ (91,131) $ (100,625) $ (66,174) $ (62,058) $ (45,051)  
Cara Therapeutics, Inc.                      
Nature Of Business [Line Items]                      
Date of formation           Jul. 02, 2004          
Restructuring and related cost, percentage of workforce reduction       70.00% 50.00%            
Proceeds from equity and debt financing           $ 520,700          
Number of follow-on public offerings | Offering           4          
Unrestricted cash and cash equivalents and marketable securities           $ 37,903          
Stock split conversion ratio     0.083                
Reverse stock split fractional shares issued | shares     0     0          
Stockholders' equity           $ (4,593) $ (8,073) $ 29,803 57,085 $ 158,779 $ 227,522
License Agreement with Maruishi Pharmaceutical Co. Ltd [Member] | Cara Therapeutics, Inc.                      
Nature Of Business [Line Items]                      
Earned milestone payment                 $ 1,449    
Subsequent Event | Cara Therapeutics, Inc.                      
Nature Of Business [Line Items]                      
Stock split conversion ratio 0.333 0.33                  
CSL Vifor, Maruishi and CKDP | License and supply agreements for difelikefalin [Member] | Cara Therapeutics, Inc.                      
Nature Of Business [Line Items]                      
Amounts earned in connection with license and supply agreements           289,900          
Post-Merger Combined Company | Subsequent Event | Cara Therapeutics, Inc.                      
Nature Of Business [Line Items]                      
Minimum percentage ownership for legacy Tvardi stockholders, directors and/or entities affiliated with Legacy Tvardi that entered into Registration Rights Agreement 5.00%                    
Merger registration rights agreement period P45D                    
Affiliated Entity [Member] | Vifor International Ltd. | Cara Therapeutics, Inc.                      
Nature Of Business [Line Items]                      
Proceeds from the sale of common stock under license agreement with Vifor International           $ 98,000